Journal of Cardiac Failure
Volume 15, Issue 7 , Pages 565-571 , September 2009

Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical Outcomes

  • Slava Epelman, MD, PhD

      Affiliations

    • Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Texas
    • ,
  • Kevin Shrestha, BA

      Affiliations

    • Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Richard W. Troughton, MBBS

      Affiliations

    • Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    • ,
  • Gary S. Francis, MD

      Affiliations

    • Cardiovascular Disease Division, University of Minnesota Medical School, Minneapolis, Minnesota
    • ,
  • Subha Sen, PhD, DSc

      Affiliations

    • Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Allan L. Klein, MD

      Affiliations

    • Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • W.H. Wilson Tang, MD

      Affiliations

    • Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationReprints requests: W. H. Wilson Tang, MD, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, J3-4, Cleveland, OH 44195. Tel: (216) 444-2121; Fax: (216) 445-6165.

Received 16 January 2009 ,Accepted 26 January 2009.

References 

  1. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105:27S–31S
  2. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–2318
  3. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2006;91:163–198
  4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82–C97
  5. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45–51
  6. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de BI, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258–8263
  7. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–14843
  8. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292:736–742
  9. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548–1550
  10. Greenberg B. An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. J Am Coll Cardiol. 2008;52:755–757
  11. Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GA, Almeida AP, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE 0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:1113–1119
  12. Epelman S, Tang WH, Chen SY, Francis GS, Sen S. Detection of soluble angiotensin converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008;52:750–754
  13. Troughton RW, Prior DL, Frampton CM, Nash PJ, Pereira JJ, Martin M, et al. Usefulness of tissue Doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). Am J Cardiol. 2005;96:257–262
  14. Tang WH, Shrestha K, Van Lente F, Troughton RW, Martin MG, Borowski AG, et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol. 2008;101:370–373
  15. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007;49:2364–2370
  16. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48:914–920
  17. Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem. 2003;278:15532–15540
  18. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003;108:1707–1712
  19. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828
  20. Zisman LS. ACE and ACE2: a tale of two enzymes. Eur Heart J. 2005;26:322–324
  21. Marcus JT, Vonk NA, Roeleveld RJ, Postmus PE, Heethaar RM, Van Rossum AC, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest. 2001;119:1761–1765
  22. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718–726
  23. Lieb W, Graf J, Gotz A, Konig IR, Mayer B, Fischer M, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men Results of the MONICA Augsburg echocardiographic substudy. J Mol Med. 2006;84:88–96
  24. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783–790
  25. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension. 2006;47:996–1002
  26. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19–26
  27. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-{alpha} convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2008;280:30113–30119
  28. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 2006;113:238–245
  29. Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res. 2006;69:646–656
  30. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75:29–39

 All decisions regarding this manuscript were made by a guest editor.

 The original Assessment of Doppler Echocardiography in Prognosis and Therapy study was supported by the 2003 American Society of Echocardiography Outcomes Research Award (Drs. Troughton and Klein), GlaxoSmithKline Pharmaceuticals, and Roche Diagnostics Inc.

PII: S1071-9164(09)00036-0

doi: 10.1016/j.cardfail.2009.01.014

Journal of Cardiac Failure
Volume 15, Issue 7 , Pages 565-571 , September 2009

Article Tools

* Image Usage & Resolution